Latest News and Updates | Cantargia

* (R) = Regulatory press releases

May 15, 2017

(R) Cantargia publishes interim report for January-March 2017

May 12, 2017

(R) Cantargia’s application to investigate the antibody product candidate CAN04 in the CANFOUR phase I/IIa clinical trial has been submitted

May 8, 2017

(R) Cantargia’s product candidate CAN04 shows good safety properties in studies performed under GLP

Apr 5, 2017

(R) Cantargia receives an Intention to Grant notice in Europe for its CAN04 product candidate

Mar 15, 2017

(R) Cantargia publishes year-end report for 2016

Feb 10, 2017

(R) Cantargia publishes outcome of the rights issue

Jan 17, 2017

(R) Cantargia publishes prospectus and certain new financial information

Jan 16, 2017

(R) Extraordinary general meeting in Cantargia

Jan 5, 2017

(R) Cantargia’s research and development to be presented at Biotech Showcase in San Francisco on 9 January 2017

Dec 20, 2016

(R) Notice of extraordinary general meeting in Cantargia AB (publ)

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye